LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Clinical trial NCT01523587 · COMPLETED
Trial details
- NCT number
- NCT01523587
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-03-05
- Primary completion
- 2013-10-21
- Enrollment
- 795
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.